KB-1388

Vunakizumab

33699

Background of Vunakizumab

Vunakizumab (also known as SHR-1314) stands as an innovative humanized monoclonal immunoglobulin of the IgG1/k isotype, directed towards targeting IL-17A. In mouse models, vunakizumab demonstrated remarkable efficiency in antagonizing IL-17, showcasing a level of efficacy in improving psoriasis akin to the tumor necrosis factor inhibitor etanercept. Initial insights gleaned from phase I studies, specifically NCT03710681 and NCT03463187, part A, provided encouraging preliminary data. These findings revealed that when administered subcutaneously at doses ranging from 80 to 240 mg every 2 weeks, vunakizumab exhibited a favorable safety profile and was well-tolerated by patients grappling with plaque psoriasis.

Specifications

Catalog Number	KB-1388
Antibody Name	Vunakizumab
Isotype	Human IgG1,kappa
FC Muations	D356E/L358M
Target	IL17A
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

C.W. Lynde et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol (2014).
M. Campa et al. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb) (2016).